A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
Trial details
- Registry ID
- NCT04126473
- Phase
- Phase 2
The FDA approved Ivacaftor on 31 Jan 2012.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X AlleleNCT04126473 | ELOX | Phase 2 | Completed | 2022-04-06Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2012-01-31Day | Ivacaftor | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA203188", "applicant_as_listed_by_fda": "VERTEX PHARMS", "brand_names": ["KALYDECO"], "active_ingredients": ["IVACAFTOR"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20120131", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |